Zumutor Biologics

United States - Cambridge, MA

• 09/12/2021
• Series A
• $6,200,000

At Zumutor, we are on a mission to develop novel novel immuno onco-therapeutics that drive transformational improvements in cancer treatment through NK cell engagement. We leverage our proven proprietary antibody discovery- INABLR™ for fast track Antibody discovery and development.
Our team works in collaboration with a world class Scientific Advisory Board with expertise in immuno-oncology and clinical development. Our lead asset (ZM008) is a first-in-class antibody that targets certain receptors that blocks NK cell inhibitory signal and enables NK cell activation to generate a potent immune response. Development is on track for an IND filing by Q2 2022 and Phase 1 clinical trial thereafter.
We are headquartered in CIC Cambridge Campus, MA and R&D is carried out at ISO certified lab in Bangalore, India

Related People

Kavitha Iyer RodriguesFounder

India - Bengaluru, Karnataka,

Expertise in core Biologics development, Management and Ops.
End to end experience with a previous start-up (Inbiopro), successfully exited the start-up to a listed Bangalore based pharma company through a strategic buy out.

Mentor/ Advisor to multiple entrepreneurs/ start-ups.

Technical experience ranging from :
Enzymes, Method Development combined with Process and Product development knowledge in Biologics. Strategic planning, management, ops, knowledge transition and successful product delivery- Biosimilars and NBEs.
Recent success with platform technologies for Novels combined with a patent portfolio.
Novel Antibody development.

LinkedIn https://www.linkedin.com/in/kavitha-iyer-rodrigues-8b8b29b/?originalSubdomain=in